ELSEVIER

Journal of Affective Disorders 48 (1998) 245–246

JOURNAL OF AFFECTIVE DISORDERS

Author index

Altshuler, L.L., see Frye, M.A. (48) 91
Asthana, H.S., Mandal, M.K., Khurana, H. and Haque-Nizamie, S.
Visuospatial and affect recognition deficit in depression (48) 57

Biondi, M., see Bonaccorso, S. (48) 75
Blumer, D., Herzog, A.G., Himmelhoch, J., Salgueiro, C.A. and Ling, F.W.
To what extent do premenstrual and interictal dysphoric disorder overlap? significance for therapy (48) 215
Bonaccorso, S., Lin, A.-h., Verkerk, R., Van Hunsel, F., Libbrecht, I., Scharpé, S., DeClerck, L., Biondi, M., Janca, A. and Maes, M.
Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers (48) 75
Bowers, M.B., see Mazure, C.M. (48) 83
Bromet, E.J., see Carlson, G.A. (48) 199
Burrows, G., see Perenyi, A. (48) 163

Carlson, G.A., Bromet, E.J. and Jandorf, L.
Conduct disorder and mania: what does it mean in adults (48) 199
Cooke, L.B. and Thompson, C.
Seasonal Affective Disorder and response to light in two patients with learning disability (48) 145
Corá-Locatelli, G., see Frye, M.A. (48) 91

De Boeck, P., see de Bonis, M. (48) 191
de Bonis, M., De Boeck, P., Lida-Pulik, H., Hourtané, M. and Féline, A.
Self-concept and mood: A comparative study between depressed patients with and without borderline personality disorder (48) 191
DeClerck, L., see Bonaccorso, S. (48) 75
Degn, B., see Ewald, H. (48) 135
Denicoff, K., see Frye, M.A. (48) 91
Dewhurst, J., see Wilhelm, K. (48) 37
Dunn, R.T., see Frye, M.A. (48) 91

Edwards, R., Peet, M., Shay, J. and Horrobin, D.
Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients (48) 149
Ewald, H., Flint, T., Degn, B., Mors, O. and Kruse, T.A.
A functional variant of the serotonin transporter gene in families with bipolar affective disorder (48) 135

Féline, A., see de Bonis, M. (48) 191
Flint, T., see Ewald, H. (48) 135
Frye, M.A., Ketter, T.A., Altshuler, L.L., Denicoff, K., Dunn, R.T., Kimbrell, T.A., Corá-Locatelli, G. and Post, R.M.
Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics (48) 91

Goodyer, I.M., see Tamplin, A. (48) 1
Graw, P., Haug, H.-J., Leonhardt, G. and Wirz-Justice, A.
Sleep deprivation response in seasonal affective disorder during a 40-h constant routine (48) 69

Hadzi-Pavlovic, D., see Manicavasagar, V. (48) 181
Hakko, H., see Räsänen, P. (48) 63
Hanafusa, I., see Okano, T. (48) 233
Haque-Nizamie, S., see Asthana, H.S. (48) 57
Haug, H.-J., see Graw, P. (48) 69
Hayashi, M., see Okano, T. (48) 233
Herbert, J., see Tamplin, A. (48) 1
Herzog, A.G., see Blumer, D. (48) 215
Hildebrandt, G., see Moser, M. (48) 115
Himmelhoch, J., see Blumer, D. (48) 215
Hoehn-Saric, R., see Moser, M. (48) 115
Hopwood, M., see Perenyi, A. (48) 163
Horrobin, D., see Edwards, R. (48) 149
Hourtané, M., see de Bonis, M. (48) 191

Janca, A., see Bonaccorso, S. (48) 75
Jandorf, L., see Carlson, G.A. (48) 199
Judd, L.L., see Rapaport, M.H. (48) 227

Kaneko, E., see Okano, T. (48) 233
Ketter, T.A., see Frye, M.A. (48) 91
Khurana, H., see Asthana, H.S. (48) 57
Kimbrell, T.A., see Frye, M.A. (48) 91
Kline Leidy, N., Palmer, C., Murray, M., Robb, J. and Revicki, D.A.
Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures (48) 207

S0165-0327(97)00186-9

Kruse, T.A., see Ewald, H. (48) 135
Kumar, R., see Okano, T. (48) 233

Lehofer, M., see Moser, M. (48) 115
Leonhardt, G., see Graw, P. (48) 69
Libbrecht, I., see Bonaccorso, S. (48) 75
Lida-Pulik, H., see de Bonis, M. (48) 191
Liebmann, P., see Moser, M. (48) 115
Lin, A.-h., see Bonaccorso, S. (48) 75
Ling, F.W., see Blumer, D. (48) 215

Maes, M., see Bonaccorso, S. (48) 75
Maes, M., see Vandoolaeghe, E. (48) 105
Mandal, M.K., see Asthana, H.S. (48) 57
Manicavasagar, V., Silove, D. and Hadzi-Pavlovic, D.
Subpopulations of early separation anxiety: relevance to risk of adult anxiety disorders (48) 181
Matsuyama, A., see Okano, T. (48) 233
Mazure, C.M. and Bowers, M.B.
Pretreatment plasma HVA predicts neuroleptic response in manic psychosis (48) 83
McLeod, D.R., see Moser, M. (48) 115
Möller, H.-J., see Müller, H. (48) 15
Mors, O., see Ewald, H. (48) 135
Moser, M., Lehofer, M., Hoehn-Saric, R., McLeod, D.R., Hildebrandt, G., Steinbrenner, B., Voica, M., Liebmann, P. and Zapotoczky, H.-G.
Increased heart rate in depressed subjects in spite of unchanged autonomic balance? (48) 115
Müller, H. and Möller, H.-J.
Methodological problems in the estimation of the onset of the antidepressant effect (48) 15
Murray, M., see Kline Leidy, N. (48) 207

Nomura, J., see Okano, T. (48) 233
Norman, T., see Perenyi, A. (48) 163
Nuyten, D., see Vandoolaeghe, E. (48) 105

Okano, T., Nomura, J., Kumar, R., Kaneko, E., Tamaki, R., Hanafusa, I., Hayashi, M. and Matsuyama, A.
An epidemiological and clinical investigation of postpartum psychiatric illness in Japanese mothers (48) 233

Palmer, C., see Kline Leidy, N. (48) 207
Parker, G., see Wilhelm, K. (48) 37
Peet, M., see Edwards, R. (48) 149
Perenyi, A., Norman, T., Hopwood, M. and Burrows, G.
Negative symptoms, depression and parkinsonian symptoms in chronic, hospitalised schizophrenic patients (48) 163
Post, R.M., see Frye, M.A. (48) 91
Poutanen, O., see Salokangas, R.K.R. (48) 171

Rabkin, J.G., see Seidman, S.N. (48) 157
Rapaport, M.H. and Judd, L.L.
Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment (48) 227
Räsänen, P., Tiihonen, J. and Hakko, H.
The incidence and onset-age of hospitalized bipolar affective disorder in Finland (48) 63
Revicki, D.A., see Kline Leidy, N. (48) 207
Revicki, D.A. and Wood, M.
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications (48) 25
Robb, J., see Kline Leidy, N. (48) 207

Salgueiro, C.A., see Blumer, D. (48) 215
Salokangas, R.K.R. and Poutanen, O.
Risk factors for depression in primary care. Findings of the TADEP project (48) 171
Scharpé, S., see Bonaccorso, S. (48) 75
Seidman, S.N. and Rabkin, J.G.
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression (48) 157
Shay, J., see Edwards, R. (48) 149
Silove, D., see Manicavasagar, V. (48) 181
Smeraldi, E.
Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study (48) 47
Steinbrenner, B., see Moser, M. (48) 115
Stewart, A.
Choosing an antidepressant: effectiveness based pharmacoeconomics (48) 125

Tamaki, R., see Okano, T. (48) 233
Tamplin, A., Goodyer, I.M. and Herbert, J.
Family functioning and parent general health in families of adolescents with major depressive disorder (48) 1
Thompson, C., see Cooke, L.B. (48) 145
Tiihonen, J., see Räsänen, P. (48) 63

Vandoolaeghe, E., Van Hunsel, F., Nuyten, D. and Maes, M.
Auditory event related potentials in major depression: prolonged P300 latency and increased P200 amplitude (48) 105
Van Hunsel, F., see Bonaccorso, S. (48) 75
Van Hunsel, F., see Vandoolaeghe, E. (48) 105
Verkerk, R., see Bonaccorso, S. (48) 75
Voica, M., see Moser, M. (48) 115

Wilhelm, K., Parker, G. and Dewhurst, J.
Examining sex differences in the impact of anticipated and actual life events (48) 37
Wirz-Justice, A., see Graw, P. (48) 69
Wood, M., see Revicki, D.A. (48) 25

Zapotoczky, H.-G., see Moser, M. (48) 115

ELSEVIER

Journal of Affective Disorders 48 (1998) 247–249

JOURNAL OF AFFECTIVE DISORDERS

Subject index

Admission rate; Postpartum psychiatric illness; Puerperal psychosis; Epidemiology; Phenomenology **48,** 233

Adolescent depression; Family functioning **48,** 1

Affective discrepancy; Self-concept; Depression; Borderline **48,** 191

Affective symptoms; Depression; Dependency; Neuroticism; Life change events; Sex differences **48,** 37

Affective task; Visuospatial task; Major depressives; Perceptual impairment **48,** 57

Age; Cardiac vagal tone; Respiratory sinus arrhythmia; Major depression; Pulse wave velocity; Blood pressure; Autonomous heart rate **48,** 115

Amisulpride; Dysthymia; Major depression; Fluoxetine **48,** 47

Androgens; Testosterone; Major depression; Refractory depression; Psychoendocrine; Open clinical trial **48,** 157

Antidepressant treatment; Health state utilities; Major depressive disorder; Health status assessment; Patient preferences; Health outcomes **48,** 25

Antidepressants; Onset of activity; Assessment of onset **48,** 15

Antidepressants; Fibromyalgia; Neopterin; Cellular immunity; Depression; Selective serotonin reuptake inhibitors **48,** 75

Antidepressants; Depression; Event-related potential; P300 component; Fluoxetine; Dementia **48,** 105

Antidepressants; Bipolar affective disorder; Serotonin transporter protein; SERT gene **48,** 135

Antidepressants; Minor depression; Depressive symptoms; Major depression pharmacology **48,** 227

Anxiety; Separation anxiety; Panic disorder; Attachment **48,** 181

Assessment of onset; Antidepressants; Onset of activity **48,** 15

Attachment; Separation anxiety; Panic disorder; Anxiety **48,** 181

Autonomous heart rate; Cardiac vagal tone; Respiratory sinus arrhythmia; Major depression; Age; Pulse wave velocity; Blood pressure **48,** 115

Bipolar; Mania; Conduct disorder **48,** 199

Bipolar affective disorder; Antidepressants; Serotonin transporter protein; SERT gene **48,** 135

Bipolar Disorder; Mania; Incidence; Prevalence **48,** 63

Bipolar disorder; Clozapine; Neuroleptics **48,** 91

Bipolar disorder; Quality of life; Psychometric evaluation; Measurement **48,** 207

Blood pressure; Cardiac vagal tone; Respiratory sinus arrhythmia; Major depression; Age; Pulse wave velocity; Autonomous heart rate **48,** 115

Borderline; Self-concept; Affective discrepancy; Depression **48,** 191

Cardiac vagal tone; Respiratory sinus arrhythmia; Major depression; Age; Pulse wave velocity; Blood pressure; Autonomous heart rate **48,** 115

Cell membranes; Depression; Polyunsaturated fatty acids; Phospholipid; Diet **48,** 149

Cellular immunity; Fibromyalgia; Neopterin; Depression; Selective serotonin reuptake inhibitors; Antidepressants **48,** 75

Clozapine; Bipolar disorder; Neuroleptics **48,** 91

Conduct disorder; Bipolar; Mania **48,** 199

Costs; SSRIs; TCAs; Economics; Effectiveness **48,** 125

Dementia; Depression; Event-related potential; P300 component; Antidepressants; Fluoxetine **48,** 105

Dependency; Affective symptoms; Depression; Neuroticism; Life change events; Sex differences **48,** 37

Depression; Affective symptoms; Dependency; Neuroticism; Life change events; Sex differences **48,** 37

Depression; Fibromyalgia; Neopterin; Cellular immunity; Selective serotonin reuptake inhibitors; Antidepressants **48,** 75

Depression; Event-related potential; P300 component; Antidepressants; Fluoxetine; Dementia **48,** 105

Depression; Polyunsaturated fatty acids; Phospholipid; Cell membranes; Diet **48,** 149

Depression; Risk factors; Primary care **48,** 171

S0165-0327(97)00187-0

Depression; Self-concept; Affective discrepancy; Borderline **48,** 191

Depressive symptoms; Schizophrenia; Negative symptoms; Parkinsonian symptoms **48,** 163

Depressive symptoms; Minor depression; Major depression pharmacology; Antidepressants **48,** 227

Diet; Depression; Polyunsaturated fatty acids; Phospholipid; Cell membranes **48,** 149

Dysthymia; Major depression; Fluoxetine; Amisulpride **48,** 47

Economics; SSRIs; TCAs; Costs; Effectiveness **48,** 125

Effectiveness; SSRIs; TCAs; Economics; Costs **48,** 125

Epidemiology; Postpartum psychiatric illness; Admission rate; Puerperal psychosis; Phenomenology **48,** 233

Event-related potential; Depression; P300 component; Antidepressants; Fluoxetine; Dementia **48,** 105

Family functioning; Adolescent depression **48,** 1

Fibromyalgia; Neopterin; Cellular immunity; Depression; Selective serotonin reuptake inhibitors; Antidepressants **48,** 75

Fluoxetine; Dysthymia; Major depression; Amisulpride **48,** 47

Fluoxetine; Depression; Event-related potential; P300 component; Antidepressants; Dementia **48,** 105

Health outcomes; Health state utilities; Major depressive disorder; Health status assessment; Patient preferences; Antidepressant treatment **48,** 25

Health state utilities; Major depressive disorder; Health status assessment; Patient preferences; Antidepressant treatment; Health outcomes **48,** 25

Health status assessment; Health state utilities; Major depressive disorder; Patient preferences; Antidepressant treatment; Health outcomes **48,** 25

Homovanillic acid (HVA); Mania; Methoxyhydroxyphenylethyleneglycol (MHPG); Neuroleptic response **48,** 83

Incidence; Bipolar Disorder; Mania; Prevalence **48,** 63

Interictal dysphoric disorder; Premenstrual dysphoric disorder; Treatment for affective disorder of epilepsy; Treatment for premenstrual dysphoria **48,** 215

Learning disability; Seasonal Affective Disorder; Phototherapy **48,** 145

Life change events; Affective symptoms; Depression; Dependency; Neuroticism; Sex differences **48,** 37

Major depression; Dysthymia; Fluoxetine; Amisulpride **48,** 47

Major depression; Cardiac vagal tone; Respiratory sinus arrhythmia; Age; Pulse wave velocity; Blood pressure; Autonomous heart rate **48,** 115

Major depression; Testosterone; Androgens; Refractory depression; Psychoendocrine; Open clinical trial **48,** 157

Major depression pharmacology; Minor depression; Depressive symptoms; Antidepressants **48,** 227

Major depressive disorder; Health state utilities; Health status assessment; Patient preferences; Antidepressant treatment; Health outcomes **48,** 25

Major depressives; Visuospatial task; Affective task; Perceptual impairment **48,** 57

Mania; Bipolar Disorder; Incidence; Prevalence **48,** 63

Mania; Homovanillic acid (HVA); Methoxyhydroxyphenylethyleneglycol (MHPG); Neuroleptic response **48,** 83

Mania; Bipolar; Conduct disorder **48,** 199

Measurement; Quality of life; Bipolar disorder; Psychometric evaluation **48,** 207

Methoxyhydroxyphenylethyleneglycol (MHPG); Mania; Homovanillic acid (HVA); Neuroleptic response **48,** 83

Minor depression; Depressive symptoms; Major depression pharmacology; Antidepressants **48,** 227

Negative symptoms; Schizophrenia; Depressive symptoms; Parkinsonian symptoms **48,** 163

Neopterin; Fibromyalgia; Cellular immunity; Depression; Selective serotonin reuptake inhibitors; Antidepressants **48,** 75

Neuroleptic response; Mania; Homovanillic acid (HVA); Methoxyhydroxyphenylethyleneglycol (MHPG) **48,** 83

Neuroleptics; Clozapine; Bipolar disorder **48,** 91

Neuroticism; Affective symptoms; Depression; Dependency; Life change events; Sex differences **48,** 37

Onset of activity; Antidepressants; Assessment of onset **48,** 15

Open clinical trial; Testosterone; Major depression; Androgens; Refractory depression; Psychoendocrine **48,** 157

P300 component; Depression; Event-related potential; Antidepressants; Fluoxetine; Dementia **48,** 105

Panic disorder; Separation anxiety; Anxiety; Attachment **48,** 181

Parkinsonian symptoms; Schizophrenia; Depressive symptoms; Negative symptoms **48,** 163

Patient preferences; Health state utilities; Major depressive disorder; Health status assessment; Antidepressant treatment; Health outcomes **48,** 25

Perceptual impairment; Visuospatial task; Affective task; Major depressives **48,** 57

Phenomenology; Postpartum psychiatric illness; Admission rate; Puerperal psychosis; Epidemiology **48,** 233

Phospholipid; Depression; Polyunsaturated fatty acids; Cell membranes; Diet **48,** 149

Phototherapy; Seasonal Affective Disorder; Learning disability **48,** 145

Polyunsaturated fatty acids; Depression; Phospholipid; Cell membranes; Diet **48,** 149

Postpartum psychiatric illness; Admission rate; Puerperal psychosis; Epidemiology; Phenomenology **48,** 233

Premenstrual dysphoric disorder; Interictal dysphoric disorder; Treatment for affective disorder of epilepsy; Treatment for premenstrual dysphoria **48,** 215

Prevalence; Bipolar Disorder; Mania; Incidence **48,** 63

Primary care; Risk factors; Depression **48,** 171

Psychoendocrine; Testosterone; Major depression; Androgens; Refractory depression; Open clinical trial **48,** 157

Psychometric evaluation; Quality of life; Bipolar disorder; Measurement **48,** 207

Puerperal psychosis; Postpartum psychiatric illness; Admission rate; Epidemiology; Phenomenology **48,** 233

Pulse wave velocity; Cardiac vagal tone; Respiratory sinus arrhythmia; Major depression; Age; Blood pressure; Autonomous heart rate **48,** 115

Quality of life; Bipolar disorder; Psychometric evaluation; Measurement **48,** 207

Refractory depression; Testosterone; Major depression; Androgens; Psychoendocrine; Open clinical trial **48,** 157

Respiratory sinus arrhythmia; Cardiac vagal tone; Major depression; Age; Pulse wave velocity; Blood pressure; Autonomous heart rate **48,** 115

Response criteria; Seasonal affective disorder; Sleep deprivation **48,** 69

Risk factors; Depression; Primary care **48,** 171

Schizophrenia; Depressive symptoms; Negative symptoms; Parkinsonian symptoms **48,** 163

Seasonal affective disorder; Sleep deprivation; Response criteria **48,** 69

Seasonal Affective Disorder; Learning disability; Phototherapy **48,** 145

Selective serotonin reuptake inhibitors; Fibromyalgia; Neopterin; Cellular immunity; Depression; Antidepressants **48,** 75

Self-concept; Affective discrepancy; Depression; Borderline **48,** 191

Separation anxiety; Panic disorder; Anxiety; Attachment **48,** 181

Serotonin transporter protein; Antidepressants; Bipolar affective disorder; SERT gene **48,** 135

SERT gene; Antidepressants; Bipolar affective disorder; Serotonin transporter protein **48,** 135

Sex differences; Affective symptoms; Depression; Dependency; Neuroticism; Life change events **48,** 37

Sleep deprivation; Seasonal affective disorder; Response criteria **48,** 69

SSRIs; TCAs; Economics; Costs; Effectiveness **48,** 125

TCAs; SSRIs; Economics; Costs; Effectiveness **48,** 125

Testosterone; Major depression; Androgens; Refractory depression; Psychoendocrine; Open clinical trial **48,** 157

Treatment for affective disorder of epilepsy; Premenstrual dysphoric disorder; Interictal dysphoric disorder; Treatment for premenstrual dysphoria **48,** 215

Treatment for premenstrual dysphoria; Premenstrual dysphoric disorder; Interictal dysphoric disorder; Treatment for affective disorder of epilepsy **48,** 215

Visuospatial task; Affective task; Major depressives; Perceptual impairment **48,** 57